Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Profit After Tax: 2010-2025

Historic Profit After Tax for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -$3.2 million.

  • Anika Therapeutics' Profit After Tax rose 89.39% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year increase of 65.43%. This contributed to the annual value of -$56.4 million for FY2024, which is 31.79% up from last year.
  • Latest data reveals that Anika Therapeutics reported Profit After Tax of -$3.2 million as of Q3 2025, which was up 31.68% from -$4.6 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Profit After Tax registered a high of $6.5 million during Q2 2021, and its lowest value of -$63.0 million during Q4 2023.
  • Moreover, its 3-year median value for Profit After Tax was -$4.9 million (2025), whereas its average is -$14.0 million.
  • In the last 5 years, Anika Therapeutics' Profit After Tax soared by 184.73% in 2021 and then slumped by 1,183.62% in 2023.
  • Over the past 5 years, Anika Therapeutics' Profit After Tax (Quarterly) stood at -$5.8 million in 2021, then increased by 15.28% to -$4.9 million in 2022, then tumbled by 1,183.62% to -$63.0 million in 2023, then surged by 65.29% to -$21.9 million in 2024, then spiked by 89.39% to -$3.2 million in 2025.
  • Its Profit After Tax stands at -$3.2 million for Q3 2025, versus -$4.6 million for Q2 2025 and -$4.9 million for Q1 2025.